Forum

U.S. adult cigarette smoking has fallen below 10% for the first time, marking a major milestone in the decline of smoking. Explore the latest data on smoking, and the changing nicotine landscape.

A recent scientific review of the current evidence on the health effects of nicotine confirms it is addictive, but carries few direct health risks on its own. We look at what the U.S. can learn from the UK in terms of talking about tobacco harm reduction.

The FDA just made one of the biggest nicotine pouch announcements in years. We break down what this means for adult users in the US.

The WHO’s first nicotine pouch report has renewed global debate around youth protection, marketing restrictions, and how evidence-based regulation can preserve legal access for adults who already use nicotine.

Tossing and turning at night? Find out more about the relationship between nicotine and sleep.

New York is considering restrictions on flavored nicotine pouches. Here’s what adult consumers should know and how to share their perspective with lawmakers.

After testifying in the state capitol last month, we're pleased to see Oregon's proposed bill to enforce a face-to-face sales requirement for nicotine products has been rejected.

An analysis of national retail data reveals clear differences in how urban and rural consumers purchase oral nicotine pouches. 

A new study examines how adult nicotine purchasing trends are changing in Sweden and Norway. What do these shifts reveal about the evolving oral nicotine market?

ZYN's health claims held up under scientific scrutiny at a recent public hearing. This is a positive sign as we await the FDA's final decision regarding their MRTP application.

We surveyed 1,000 adults about their New Year's resolutions and found a lot of them are re-thinking their relationship to alcohol, cannabis, and tobacco.

A public hearing later this month will determine whether or not ZYN can be classified as a Modified Risk Tobacco Product. We're all for it, and here's why.